CA2942605C - Methods for identifying a biomarker indicative of a reduced drug response using a thermal shift assay - Google Patents

Methods for identifying a biomarker indicative of a reduced drug response using a thermal shift assay Download PDF

Info

Publication number
CA2942605C
CA2942605C CA2942605A CA2942605A CA2942605C CA 2942605 C CA2942605 C CA 2942605C CA 2942605 A CA2942605 A CA 2942605A CA 2942605 A CA2942605 A CA 2942605A CA 2942605 C CA2942605 C CA 2942605C
Authority
CA
Canada
Prior art keywords
drug
sample
patient
protein
responsive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2942605A
Other languages
English (en)
French (fr)
Other versions
CA2942605A1 (en
Inventor
Daniel MARTINEZ MOLINA
Par Nordlund
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pelago Bioscience AB
Original Assignee
Pelago Bioscience AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pelago Bioscience AB filed Critical Pelago Bioscience AB
Publication of CA2942605A1 publication Critical patent/CA2942605A1/en
Application granted granted Critical
Publication of CA2942605C publication Critical patent/CA2942605C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
CA2942605A 2014-03-25 2015-03-25 Methods for identifying a biomarker indicative of a reduced drug response using a thermal shift assay Active CA2942605C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1405327.6 2014-03-25
GB1405327.6A GB2524519B (en) 2014-03-25 2014-03-25 Methods for identifying a biomarker indicative of a reduced drug response using a thermal shift assay
PCT/GB2015/050895 WO2015145151A1 (en) 2014-03-25 2015-03-25 Method for identifying a biomarker indicative of a reduced drug response using a thermal shift assay

Publications (2)

Publication Number Publication Date
CA2942605A1 CA2942605A1 (en) 2015-10-01
CA2942605C true CA2942605C (en) 2023-08-22

Family

ID=50686878

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2942605A Active CA2942605C (en) 2014-03-25 2015-03-25 Methods for identifying a biomarker indicative of a reduced drug response using a thermal shift assay

Country Status (10)

Country Link
US (1) US11480578B2 (da)
EP (1) EP3123175B1 (da)
JP (1) JP6645981B2 (da)
CN (1) CN106233144B (da)
CA (1) CA2942605C (da)
DK (1) DK3123175T3 (da)
ES (1) ES2792680T3 (da)
GB (1) GB2524519B (da)
SG (1) SG11201607149WA (da)
WO (1) WO2015145151A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2524519B (en) 2014-03-25 2019-11-06 Pelago Bioscience AB Methods for identifying a biomarker indicative of a reduced drug response using a thermal shift assay
KR101862198B1 (ko) * 2016-09-30 2018-05-30 (주)스파크바이오파마 2차원 겔 전기영동에서의 열 안정성 변화-기반 형광 차이를 이용한 표적 단백질의 규명 방법
HUE055970T2 (hu) * 2016-12-20 2022-01-28 Treat4Life Ab Eljárás BRAF mutációk és vad típusú BRAF fehérje meghatározására tömegspektrometria segítségével
WO2019035773A1 (en) * 2017-08-18 2019-02-21 Agency For Science, Technology And Research METHODS OF IDENTIFYING PROTEIN INTERACTION
CN113160878B (zh) * 2021-04-16 2022-06-10 西北工业大学 一种天然药物分子靶标蛋白的冷启动筛选方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9525481D0 (en) * 1995-12-13 1996-02-14 Royston M C Novel method
KR20000011069A (ko) * 1996-05-09 2000-02-25 스리-디멘셔널 파마슈티컬스 인코포레이티드 리간드 개발 및 다변수 단백질 화학의 최적화를 위한미량이식판 열 이동 분석 및 그 장치
NZ504483A (en) * 1997-11-12 2002-11-26 Dimensional Pharm Inc High throughput method for functionally classifying proteins by contacting the protein with different molecules and determining the effect on the proteins stability
US7294472B2 (en) * 2001-03-14 2007-11-13 Caden Biosciences Method for identifying modulators of G protein coupled receptor signaling
US7537891B2 (en) * 2002-08-27 2009-05-26 Bristol-Myers Squibb Company Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells
AU2003278725A1 (en) * 2002-08-27 2004-03-19 Bristol-Myers Squibb Company Polynucleotide predictor set for identifying protein tyrosine kinase modulators
US20060019284A1 (en) * 2004-06-30 2006-01-26 Fei Huang Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in lung cancer cells
WO2007067476A2 (en) * 2005-12-05 2007-06-14 Merck & Co., Inc. Methods for predicting treatment response based on the expression profiles of protein and transcription biomakers
GB0606096D0 (en) * 2006-03-27 2006-05-03 Cbmm Sa Screening method
US20080096208A1 (en) * 2006-09-06 2008-04-24 Connors Richard W Biomarkers for assessing response to c-met treatment
EP1918714A1 (en) * 2006-11-02 2008-05-07 Koninklijke Philips Electronics N.V. Compounds and methods for double labelling of polypeptides to allow multiplexing in mass spectrometric analysis
US8476081B2 (en) * 2009-09-21 2013-07-02 Janssen Pharmaceutica Nv Assay for evaluating affinity and specificity of ligand-albumin binding
CA2777934A1 (en) * 2009-10-20 2011-04-28 Prometheus Laboratories Inc. Proximity-mediated assays for detecting oncogenic fusion proteins
EP2656068A1 (en) * 2010-12-22 2013-10-30 Cellzome GmbH A method for the evaluation of compound-target interactions across species
US20120194522A1 (en) * 2011-02-01 2012-08-02 Life Technologies Corporation Systems and Methods for the Analysis of Protein Melt Curve Data
GB201106548D0 (en) * 2011-04-18 2011-06-01 Evitraproteoma Ab A method for determining ligand binding to a target protein using a thermal shift assahy
US9523693B2 (en) * 2011-04-18 2016-12-20 Biotarget Engagement Interest Group Ab Methods for determining ligand binding to a target protein using a thermal shift assay
US9261497B2 (en) * 2012-10-16 2016-02-16 New York University Method of treating cancer with modulators of SCFSkp2
GB2524519B (en) 2014-03-25 2019-11-06 Pelago Bioscience AB Methods for identifying a biomarker indicative of a reduced drug response using a thermal shift assay

Also Published As

Publication number Publication date
US20180172697A1 (en) 2018-06-21
GB2524519A (en) 2015-09-30
DK3123175T3 (da) 2020-05-25
CN106233144B (zh) 2019-06-21
GB201405327D0 (en) 2014-05-07
CN106233144A (zh) 2016-12-14
JP2017508983A (ja) 2017-03-30
EP3123175A1 (en) 2017-02-01
GB2524519B (en) 2019-11-06
JP6645981B2 (ja) 2020-02-14
CA2942605A1 (en) 2015-10-01
WO2015145151A1 (en) 2015-10-01
SG11201607149WA (en) 2016-10-28
EP3123175B1 (en) 2020-04-22
ES2792680T3 (es) 2020-11-11
US11480578B2 (en) 2022-10-25

Similar Documents

Publication Publication Date Title
CA2942605C (en) Methods for identifying a biomarker indicative of a reduced drug response using a thermal shift assay
KR101553723B1 (ko) 항체­기반 어레이를 사용한 폐 암 치료를 위한 약물 선별법
JP5154557B2 (ja) 希少循環細胞における多様なシグナル伝達物質検出のための抗体に基づくアレイ
DK2699910T3 (da) Fremgangsmåde til at bestemme ligand binding til et målprotein under anvendelse af et termisk shift assay
JP2021511510A (ja) 疾患および障害の診断および予後診断のためのエキソソームおよびエキソソームバイオマーカーの検出
US7510850B2 (en) Isolation of the mitotic spindle matrix and its methods of use
Minamida et al. Profilin 1 overexpression in renal cell carcinoma
EP3867640B1 (en) Method for identifying a chemical compound or agent inducing ubiquitination of a protein of interest
Kumar et al. Quantitative proteomics for identifying biomarkers for tuberculous meningitis
JP7177096B2 (ja) 乳癌を検出する方法
SI24638A (sl) Fluorometrična imunska metoda za določanje protiteles proti dvojnoverižni DNA
Murray et al. Quantitative proteomic profiling of pleomorphic human sarcoma identifies CLIC1 as a dominant pro-oncogenic receptor expressed in diverse sarcoma types
US20120190563A1 (en) Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor
US20120115745A1 (en) Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor
EP2567232A1 (en) Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor
WO2017078787A1 (en) Protein quantitation in multicellular tissue specimens
Karakaş et al. Immunoreactivity against SLC3A2 in high grade gliomas displays positive correlation with glioblastoma patient survival: Potential target for glioma diagnosis and therapy
Rollins Elucidating the Role of RNA Binding Proteins in Maintaining Genome Integrity
Pereira et al. Proteomic Analysis of HCC-1954 and MCF-7 Cell Lines Highlights Crosstalk between v and 1 Integrins, E-Cadherin and HER-2
KR101432714B1 (ko) 벤조안트라센 오염 검출을 위한 마커 및 키트
Leonardi et al. Potential Applications of Aptamers for Targeting Senescent Cells
JP2024523046A (ja) バイオマーカー及びそれらの使用
Lakshmikantha et al. Microsomal membrane proteome of low grade diffuse astrocytomas: Differentially expressed proteins and candidate surveillance biomarkers

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200128

EEER Examination request

Effective date: 20200128

EEER Examination request

Effective date: 20200128

EEER Examination request

Effective date: 20200128

EEER Examination request

Effective date: 20200128

EEER Examination request

Effective date: 20200128